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Management of cystic fibrosis in adults
Non-drug treatments
Because sputum of increased viscosity will lead to 
worsening airway obstruction, patients are strongly 
encouraged to perform active airway clearance 
techniques such as autogenic drainage or positive 
expiratory pressure to maintain their health. A flutter 
device can be effective in some patients. This is a 
hand-held oscillating positive pressure device (see 
Fig. 1). The patient breathes out through the device 
against an alternating resistance. Back pressure leads 
to small airway opening which in turn promotes 
increased airway clearance.  
Mucolytics
Mucolytics are given to improve the viscosity of 
mucus and aid its clearance. Nebulised dornase 
alpha (2.5 mg) acts by breaking down DNA, which 
contributes to the high viscosity of the sputum.2 
Responses are variable so patients can only continue 
this treatment on the Pharmaceutical Benefits 
Scheme if their lung function improves by 10% 
(forced expiratory volume in 1 second – FEV1) after a 
one month trial. There are very few adverse effects 
although haemoptysis has been reported. 
Nebulised hypertonic saline, typically 5 mL of 6% 
solution twice a day, is also used to reduce mucus 
viscosity. The high salt content is thought to cause 
water to influx into the airway lumen and assist with 
mucus clearance. Many patients benefit from using 
this medication.3 However, some patients may not 
tolerate it because of severe bronchospasm or cough. 
Inhaled mannitol powder has recently become 
available for cystic fibrosis.4 A standard dose is  
400 mg twice a day. Its high sugar content elevates 
the osmolality within the airway leading to water 
influx into the lumen. Cough can be a limiting factor  
in adherence. 
Antibiotics
Antibiotics are administered for several possible 
purposes: 
 đ to eradicate or delay the onset of P. aeruginosa 
colonisation
 đ to maintain lung function
 đ to intensify treatment of a pulmonary 
exacerbation. 
Eradication protocols contain intravenous 
antipseudomonal antibiotics followed by a prolonged 
course of nebulised colistin and oral ciprofloxacin. 
SUMMARY
Cystic fibrosis is the most common lethal 
autosomal recessive disease. Mutations in a 
membrane protein cause secretions such as 
mucus and digestive juices to be abnormally 
thick and sticky. 
Respiratory symptoms tend to dominate the 
course of the disease but other complications 
include gastrointestinal disorders, male 
infertility, osteoporosis, diabetes and 
rhinosinusitis. 
Due to improved treatments in childhood, the 
life expectancy of patients with cystic fibrosis 
has increased. Doctors are now more likely to 
encounter adults with this disease so being 
aware of current and emerging therapies 
used in their management is important. 
Introduction 
The management of patients with cystic fibrosis has 
improved over the past 30 years and most people 
now survive into adulthood. In an Australian study, 
the mean age at death in 2005 was 26.6 years.1 As a 
result doctors other than paediatricians are managing 
the complications of this disease. 
Cystic fibrosis is the most common lethal autosomal 
recessive disease and occurs in 1 in 2000 people. 
A defect in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, which regulates 
the transport of chloride and other electrolytes, 
causes secretions to be abnormally thick and sticky. 
These secretions build up in the upper airways and 
the ducts of various organs affecting the lungs, 
gastrointestinal tract, pancreas, liver, sinuses, 
sweat glands and reproductive system. Respiratory 
problems, such as chronic infection and inflammation, 
tend to dominate the clinical course and a patient’s 
respiratory status ultimately determines their 
prognosis.
Managing respiratory disease
There are a number of respiratory complications 
including acute pulmonary exacerbations, asthma, 
haemoptysis, pneumothorax and pneumonia. 
Pseudomonas aeruginosa is the predominant 
organism, however other organisms may colonise the 
respiratory tract and warrant therapy on occasions. 
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Maintenance strategies include long-term treatment 
with oral azithromycin.5,6 Nebulised tobramycin or 
colistin cycling over some months to years, and other 
oral antibiotics sometimes given in a rotating fashion, 
are commonly used. However, there is no evidence for 
this practice. 
Exacerbations
An exacerbation is difficult to define. One definition7 
requires the patient to have two out of a possible 
seven symptoms – including fever, increased sputum 
volume (by 50%) and increased cough frequency (by 
50%) as well as at least one of three additional clinical 
criteria such as a drop of 10% in forced vital capacity.
As the majority of adult patients are colonised with  
P. aeruginosa, therapies are directed at this organism. 
For mild exacerbations, oral ciprofloxacin (2 week 
course) and nebulised aminoglycoside (2–4 week 
course) are used. Typically, nebulised tobramycin 
80–160 mg twice a day is given. Nebulised colistin 
(for example 1–2 million units twice a day) could be 
used as an alternative to tobramycin. This trial switch 
in therapy would be indicated if the patient was not 
responding to nebulised tobramycin or was intolerant 
(for example developing bronchospasm). Nebulised 
antibiotics rarely cause systemic adverse effects but 
with time can cause hearing impairment or balance 
problems in some patients. 
If P. aeruginosa is not commonly isolated from the 
patient’s sputa, a course of dicloxacillin (for example 
500 mg four times a day) for Staphylococcus aureus 
colonisation or amoxycillin/clavulanic acid (for 
example 875/125 mg twice a day) may be used. 
Other pathogens that are sometimes isolated and 
need targeted therapy include Stenotrophomonas 
maltophilia (sulfamethoxazole/trimethoprim) and 
Haemophilus influenzae (amoxycillin).
For more severe exacerbations, patients are 
hospitalised and given intravenous antibiotics typically 
with a combination of a beta lactam-derived antibiotic 
(for example ticarcillin/clavulanic acid or ceftazidime) 
with an aminoglycoside (for example tobramycin as a 
single daily dose). The duration of these treatments is 
about 10–14 days. This empirical approach is justified 
as studies have shown that sputum sensitivities are 
not a useful guide to choosing therapy.8 Often the 
choice of drugs is dictated by previous allergies 
or intolerances of various antibiotics. Because 
deteriorating patients require frequent courses of 
these antibiotics, they should be closely monitored 
for long-term complications such as renal and hearing 
impairment.
Inhaled bronchodilators
Many patients regularly use short-acting 
bronchodilators, such as salbutamol, to aid airway 
clearance and enhance delivery of other inhaled 
drugs. Research on tiotropium, a long-acting 
anticholinergic, is just beginning. 
Inhaled steroids
Some patients with cystic fibrosis take these 
medications regularly to assist with asthma control or 
lung inflammation. Adherence and effectiveness are 
very variable. There is limited evidence for bacterial 
contamination of inhaler devices but it may occur.9
Rhinosinusitis
Rhinosinusitis is very common in cystic fibrosis and 
can be managed with a combination of saline sprays, 
inhaled steroids and sometimes oral prednisolone. 
Surgery may be required in some cases. 
Managing gastrointestinal disorders
Maintenance of nutrition is critical for patients with 
cystic fibrosis. Mechanisms for weight loss include 
suboptimal pancreatic function, diabetes, chronic 
anorexia related to chronic suppurative lung disease, 
the catabolic effect of chronic respiratory infections 
and the increased work of breathing. 
Patients can suffer from a range of gastrointestinal 
disorders including pancreatic insufficiency, liver 
disease (cirrhosis in 5% of patients), bacterial 
overgrowth and distal intestinal obstruction 
syndrome. About 15% of patients who are pancreatic 
sufficient can develop episodes of acute pancreatitis. 
Pancreatic enzymes
Most patients have pancreatic insufficiency and thus 
require lifelong enzyme replacement. This is titrated 
to the fat content in each meal or snack with the aim 
being to control symptoms of abdominal cramping 
pain and steatorrhoea and to maintain weight. A 
typical dose would be around 3–4 capsules with meals 
and 1–2 capsules with snacks, but this is highly variable. 
Fig. 1    Flutter device
Picture courtesy of the author
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which can then be used to fertilise the partner’s eggs 
via in vitro fertilisation. 
Pregnancy
Many women with cystic fibrosis can conceive 
naturally and should be using contraception until they 
decide to try for a pregnancy. We recommend that 
they discuss their intentions with their doctor before 
attempting to conceive. Genetic counselling is also 
important for couples planning to start a family. 
Pregnancy poses a number of challenges. Often 
women have an increased frequency of respiratory 
exacerbations as the pregnancy progresses. Nutrition 
is harder to maintain so often additional supplements 
are required. Gestational diabetes may occur. 
Adherence to therapy
As with other chronic diseases, adherence is a problem 
for many patients who often have a complicated 
therapy regimen. Team members work with the 
patient to enhance adherence using techniques such 
as motivational interviewing. Ongoing monitoring of 
adherence and appropriate advice and encouragement 
to address these problems are essential in managing 
the many challenges inherent in this chronic disease. 
New therapies
As a result of ongoing research, new therapies have 
been developed targeting specific genetic mutations. 
For example, a randomised trial with a CFTR 
potentiator (VX770) has shown improvements in 
lung function and nutrition as well as demonstrating 
a partial correction of the electrolyte imbalance 
at the cellular level (chloride levels in sweat fell 
significantly).10 The compound is administered as 
a daily tablet which enhances the function of the 
abnormal CFTR in the membrane of epithelial cells 
throughout the body. It is used in patients with one or 
two G551D cystic fibrosis mutations in the genotype. 
Conclusion
Cystic fibrosis is a complex multisystem disease which 
primarily affects the lungs and the pancreas. There 
are many therapies available to improve the health 
of the patient. Regimens tend to be quite involved so 
encouraging adherence is very important. Optimal 
management of these patients is achieved via a 
dedicated multidisciplinary team. 
Patient survival has improved dramatically over 
a number of decades. However, new challenges 
are emerging because of antibiotic resistance and 
allergies. New treatments targeting the specific CFTR 
defect are becoming more available.   
Conflict of interest: none declared
Salt and fluids
Patients are strongly encouraged to take adequate 
salt and fluid throughout the whole year. Many 
patients take 4–8 salt tablets per day depending on 
the season. Fluids are generally electrolyte solutions 
(for example Glucolyte) with patients typically 
requiring 1–3 sachets per day. 
Vitamins
Fat-soluble vitamins (namely vitamins A, D, E and K) 
are replaced by prescribing a combination therapy 
known as VitABDECK (2 tablets every morning).
Oral supplements
The most commonly used oral nutritional supplement 
is Ensure which is available as 200 mL tetrapaks. 
A number of patients would take about 2–4 of 
these per day. Other options include Ensure Plus 
(contains increased calories), Sustagen, Resource and 
Scandishakes. 
Calcium and bisphosphonates
Patients with cystic fibrosis are at increased risk 
of osteoporosis and many take oral calcium and 
additional vitamin D. Osteoporosis is monitored 
by bone mineral densitometry twice a year and is 
treated with bisphosphonates (and testosterone when 
appropriate).
Proton pump inhibitors
Gastro-oesophageal reflux is very common and often 
requires chronic therapy with a proton pump inhibitor. 
Enteral feeds
A significant minority of patients need to administer 
nutritional supplements via a self-inserted nasogastric 
tube (usually about 1 L per night) to maintain their 
body weight. Gastrostomy is occasionally required 
instead. 
Ursodeoxycholic acid
A small percentage of patients with significant 
liver dysfunction are treated with ursodeoxycholic 
acid (500 mg twice a day) in an attempt to delay 
progression of liver disease to cirrhosis. However, 
evidence for this effect is lacking. 
Diabetes 
Diabetes is caused by destruction of the endocrine 
pancreatic glands from inflammation in the exocrine 
component of the pancreas. If diabetes develops, 
insulin is usually commenced. 
Reproductive health
Male infertility is universal due to absence of the vas 
deferens. Men who want to start a family should be 
referred to a fertility centre for aspiration of sperm 
SELF-TEST 
QUESTIONS
True or false? 
5. Cough may limit the 
use of hypertonic saline 
and inhaled mannitol 
powder in patients with 
cystic fibrosis. 
6. Mild pulmonary 
exacerbations are 
usually managed 
with an intravenous 
combination of 
ticarcillin/clavulanic 
acid and tobramycin. 
Answers on page 135
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Cystic Fibrosis Australia 
Cystic Fibrosis Australia promotes health and support services for children, youth and adults with cystic 
fibrosis, and their families. With its state and territory organisations, it distributes information at national and 
international levels. 
Brochures, books, videos and information packs are available via the website, and there is an online forum for 
people to share their experiences with managing cystic fibrosis. A trust funds research into cystic fibrosis, and 
promotional events include the national 65 Roses Day (www.65rosesday.org.au). 
Contact
Phone 1800 232 823 or 02 9878 5250 
Head office Inglewood Business Centre  
 5–7 Inglewood Place 
 Baulkham Hills NSW 2153 
Website www.cysticfibrosis.org.au 
Email general@cysticfibrosisaustralia.org.au 
State and territory organisations
 CF Australian Capital Territory  info@cfact.org.au 
 CF New South Wales admin@cysticfibrosisnsw.org.au  
 CF Queensland admin@cfqld.org.au 
 CF South Australia cfsa@cfsa.org.au  
 CF Tasmania general@cftas.org.au 
 CF Victoria admin@cfv.org.au 
 CF Western Australia info@cysticfibrosiswa.org 
